Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS

Redenlab partnered with investigators in Australia and Germany to conduct dysarthria treatment trial in ataxia published in Journal of Neurology

Abstract: We aimed to provide proof-of-principle evidence that intensive home-based speech treatment can improve dysarthria in complex multisystemic degenerative ataxias, exemplified by autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Feasibility and piloting efficacy of speech training specifically tailored to cerebellar dysarthria was examined through a 4-week program in seven patients with rater-blinded assessment of intelligibility (primary outcome) and naturalness and acoustic measures of speech (secondary outcomes) performed 4 weeks before, immediately prior to, and directly after training (intraindividual control design). Speech intelligibility and naturalness improved post treatment. This provides piloting evidence that ataxia-tailored speech treatment might be effective in degenerative cerebellar disease.

See here for study details

Related Post

  • Posted on 25 January, 2024
    Exposing healthy adults to extended periods of wakefulness is known to induce changes in psychomotor functioning. The effect of fatigue...
    • Posted on 17 January, 2024
      While speech biomarkers of disease have attracted increased interest in recent years, a challenge is that features derived from signal...
      • Posted on 17 January, 2024
        Smart devices are widely available and capable of quickly recording and uploading speech segments for health-related analysis. The switch from...